TrialThe Prostate2021

Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.

Eugene Shenderov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.